MRI lesion burden as a predictor of progression and survival in smoldering multiple myeloma. Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth ...

† Median OS not reached at 21 months for eight patients with primary PCL. CE: Cyclophosphamide, etoposide; dex: Dexamethasone; M-80: Intermediate-dose melphalan ...

Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma-cell disorder present in approximately 5% of the general population over the age of 50 years. MGUS is characterized ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

Learn how KMA and LMA represent a breakthrough in treatment approaches for multiple myeloma and related disorders.

CLEVELAND, Ohio — Researchers at Case Western Reserve University School of Medicine and MetroHealth System have developed a ...